The delta-confirmed patients in the regdanvimab treatment group were generally older (P < 0.001), admitted earlier (P = 0.002), had a higher BMI ≥ 25 kg/m2 (P = 0.031), pneumonia (P = 0.017), higher CRP level (P = 0.049), and lower LDH level (P = 0.001) than those in the delta-confirmed subgroup who received supportive care. This evidence concerns the gene CRP and susceptibility to pneumonia measurement.